Clinical Trial Update: Study of Erenumab (AMG 334) in Women With Hot Flashes [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of erenumab (AMG 334) in women with vasomotor symptoms and hot flashes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hot Flashes
• Vasomotor Symptoms

Drugs mentioned

• erenumab (erenumab)

Snippet

Sponsor: Amgen | Conditions: Vasomotor Symptoms; Hot Flashes | Phase 1 | Status: COMPLETED | Results posted: 2019-01-14